New project added to the Forfait Innovation program in France

21

Mar 2023

Forfait innovation is the most advanced coverage with the evidence development program in France. The program was initiated in 2015 and is only focused on medical devices, procedures and in-vitro diagnostic technologies. The objective of the Forfait Innovation program is to provide early support for breakthrough innovation and bridge serious evidence gaps simultaneously. The program includes a government co-sponsored study. The budget comes from three sources: the Ministry of Health (experimental arm), regular statutory health insurance (control arm), and an applicant (study infrastructure).

On March 8, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic on the coverage of the INTERVAPOR system under Forfait innovation program. The INTERVAPOR bronchoscopic system for reducing lung volume by water vapor in patients with severe heterogeneous emphysema of the upper lobe is included in Forfait innovation for a period of 40 months from the date of the first inclusion in the study. The amount of the flat-rate reimbursement, including reimbursement for the procedure and associated hospitalization costs, is set at €3,903 per patient. The total number of patients likely to benefit from reimbursement is set at 300, including 150 patients under the study and 150 additional patients not included in the study (during the follow-up phase).

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

08

Jun 2023

In the period of April-May 2023, the Galician Agency for Health Technology Assessment (AVALIA-T) initiated the five health technology assessments referred to IVD, nephrology and urology, obstetrics and gynecology, pulmonary and airways as well as surgical procedures technology groups. The assessments on stereotactic virtual navigation system for percutaneous puncture as well as tumor ablation and invasive telemonitoring of pulmonary pressure in patients with heart failure were released.

Read more

06

Jun 2023

Director of MTRC Oleg Borisenko participated in the session “Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?” at the Med Tech Forum in Dublin on the 31st of May 2023. The section was moderated by Rachele Busca (Director, HTA and Real-World Evidence, EMEACLA, Edwards Lifesciences) and panelists included Daniel Bamford (Deputy Director, Medtech and Digital, Innovation, Research and Life Sciences, NHS England) and Louisa Stüwe (Ministerial eHealth Delegation, Ministry of Health and Prevention, France). Oleg presented the summary of the report on innovative payment schemes for medical technologies, commissioned in 2022 by the European industry association Med Tech Europe to MTRC. We present a summary of the presentation.

Read more

06

Jun 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May 2023. Twenty-one recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, endocrine, ENT, gastrointestinal, and orthopedic devices, as well as medical aids.

Read more

02

Jun 2023

On May 15, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, recommending the transfer to standard care for another three completed projects. The projects relate to controlling drug prescriptions in outpatient settings, evaluating the effectiveness of outpatient extensive stuttering therapy in primary school children, and the efficacy of cross-sectoral care models in psychiatry.

Read more

01

Jun 2023

On May 23, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic setting the tariffs for the medical telemonitoring activities covered by social health insurance in the context of the new framework. The tariffs will differ whether they bring an organizational or clinical (improvement in quality of life, morbidity, or mortality) benefit.

Read more